1. Preface
1.1. Report Description
1.1.1. Purpose of the Report
1.1.2. Target Audience
1.1.3. Key Offerings
1.2. Market Segmentation
1.3. Research Methodology
1.3.1. Phase I - Secondary Research
1.3.2. Phase II - Primary Research
1.3.3. Phase III - Expert Panel Review
1.3.4. Assumptions
1.3.5. Approach Adopted

2. Executive Summary
2.1. Market Snapshot: Global Recombinant Vaccines Market
2.2. Global Recombinant Vaccines Market, By Disease, 2023 (US$ Million)
2.3. Global Recombinant Vaccines Market, By Geography, 2023 (US$ Million)
2.4. Attractive Investment Proposition by Geography, 2023

3. Recombinant Vaccines Market: Competitive Analysis
3.1. Market Positioning of Key Recombinant Vaccines Market Vendors
3.2. Strategies Adopted by Recombinant Vaccines Market Vendors
3.3. Key Industry Strategies
4. Recombinant Vaccines Market: Macro Analysis & Market Dynamics
4.1. Introduction
4.2. Global Recombinant Vaccines Market Value, 2022 - 2032, (US$ Million)
4.3. Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Key Challenges
4.3.4. Key Opportunities
4.4. Impact Analysis of Drivers and Restraints
4.5. See-Saw Analysis
4.6. Porter's Five Force Model
4.6.1. Supplier Power
4.6.2. Buyer Power
4.6.3. Threat Of Substitutes
4.6.4. Threat Of New Entrants
4.6.5. Competitive Rivalry
4.7. PESTEL Analysis
4.7.1. Political Landscape
4.7.2. Economic Landscape
4.7.3. Technology Landscape
4.7.4. Legal Landscape
4.7.5. Social Landscape

5. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
5.1. Market Overview
5.2. Growth & Revenue Analysis: 2023 Versus 2032
5.3. Market Segmentation
5.3.1. Infectious Diseases
5.3.1.1. Hepatitis B Infection
5.3.1.2. Herpes Zoster Infection
5.3.1.3. Influenza Infection
5.3.1.4. Other Infectious Diseases
5.3.2. Cancer


6. North America Recombinant Vaccines Market, 2022-2032, USD (Million)
6.1. Market Overview
6.2. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
6.3.Recombinant Vaccines Market: By Region, 2022-2032, USD (Million)
6.3.1.North America
6.3.1.1. U.S.
6.3.1.1.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
6.3.1.2. Canada
6.3.1.2.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
6.3.1.3. Rest of North America
6.3.1.3.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)

7. UK and European Union Recombinant Vaccines Market, 2022-2032, USD (Million)
7.1. Market Overview
7.2. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
7.3.Recombinant Vaccines Market: By Region, 2022-2032, USD (Million)
7.3.1.UK and European Union
7.3.1.1. UK
7.3.1.1.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
7.3.1.2. Germany
7.3.1.2.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
7.3.1.3. Spain
7.3.1.3.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
7.3.1.4. Italy
7.3.1.4.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
7.3.1.5. France
7.3.1.5.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
7.3.1.6. Rest of Europe
7.3.1.6.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)

8. Asia Pacific Recombinant Vaccines Market, 2022-2032, USD (Million)
8.1. Market Overview
8.2. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
8.3.Recombinant Vaccines Market: By Region, 2022-2032, USD (Million)
8.3.1.Asia Pacific
8.3.1.1. China
8.3.1.1.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
8.3.1.2. Japan
8.3.1.2.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
8.3.1.3. India
8.3.1.3.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
8.3.1.4. Australia
8.3.1.4.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
8.3.1.5. South Korea
8.3.1.5.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
8.3.1.6. Rest of Asia Pacific
8.3.1.6.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)

9. Latin America Recombinant Vaccines Market, 2022-2032, USD (Million)
9.1. Market Overview
9.2. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
9.3.Recombinant Vaccines Market: By Region, 2022-2032, USD (Million)
9.3.1.Latin America
9.3.1.1. Brazil
9.3.1.1.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
9.3.1.2. Mexico
9.3.1.2.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
9.3.1.3. Rest of Latin America
9.3.1.3.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)

10. Middle East and Africa Recombinant Vaccines Market, 2022-2032, USD (Million)
10.1. Market Overview
10.2. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
10.3.Recombinant Vaccines Market: By Region, 2022-2032, USD (Million)
10.3.1.Middle East and Africa
10.3.1.1. GCC
10.3.1.1.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
10.3.1.2. Africa
10.3.1.2.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)
10.3.1.3. Rest of Middle East and Africa
10.3.1.3.1. Recombinant Vaccines Market: By Disease, 2022-2032, USD (Million)

11. Company Profile
11.1. Bharat Biotech
11.1.1. Company Overview
11.1.2. Financial Performance
11.1.3. Product Portfolio
11.1.4. Strategic Initiatives
11.2. GlaxoSmithKline Plc.
11.2.1. Company Overview
11.2.2. Financial Performance
11.2.3. Product Portfolio
11.2.4. Strategic Initiatives
11.3. MedImmune, LLC
11.3.1. Company Overview
11.3.2. Financial Performance
11.3.3. Product Portfolio
11.3.4. Strategic Initiatives
11.4. Merck & Co. Inc.
11.4.1. Company Overview
11.4.2. Financial Performance
11.4.3. Product Portfolio
11.4.4. Strategic Initiatives
11.5. Novartis AG
11.5.1. Company Overview
11.5.2. Financial Performance
11.5.3. Product Portfolio
11.5.4. Strategic Initiatives
11.6. Pfizer Inc.
11.6.1. Company Overview
11.6.2. Financial Performance
11.6.3. Product Portfolio
11.6.4. Strategic Initiatives
11.7. Protein Science Corporation
11.7.1. Company Overview
11.7.2. Financial Performance
11.7.3. Product Portfolio
11.7.4. Strategic Initiatives
11.8. Sanofi Aventis
11.8.1. Company Overview
11.8.2. Financial Performance
11.8.3. Product Portfolio
11.8.4. Strategic Initiatives
11.9. Serum Institute of India
11.9.1. Company Overview
11.9.2. Financial Performance
11.9.3. Product Portfolio
11.9.4. Strategic Initiatives